Medical/Pharmaceuticals

Speclipse attracts $7.7M in investments with its laser spectroscopic and artificial intelligence medical diagnosis technology

SEOUL, South Korea, Aug. 19, 2021 /PRNewswire/ -- Speclipse, a startup specializing in laser spectroscopic and AI-based medical diagnosis technologies and a member ofBorn2Global Centre, recently attracted USD 7.7 million in investments for an accumulated investment total ofUSD 13 million. ...

2021-08-19 20:30 2094

PharmAbcine Announces Submission of PCT for an Anti-ANG2 Antibody for the Treatment of Ocular Diseases

DAEJEON, South Korea, Aug. 19, 2021 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next-generation antibody therapeutics, today announced it submitted a Patent Cooperation Treaty (PCT), an international patent application, for ...

2021-08-19 20:00 1846

I-Mab Announces Establishment of Environmental, Social and Governance Committee

* I-Mab received highest first-time ESG rating among China-based biotech companies from MSCI * New majority independent ESG committee to set overall ESG strategies for the Company * Women account for two-thirds of the total workforce and over 30% of I-Mab's Board of Directors * Committed ...

2021-08-19 19:00 4918

Senhwa's Silmitasertib Receives US FDA Fast Track Designation for the Treatment of Recurrent Sonic Hedgehog Driven Medulloblastoma

TAIPEI and SAN DIEGO, Aug. 18, 2021 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a drug development company focused on first-in-class therapeutics for oncology, rare diseases, and novel coronaviruses, today announced that the US Food and Drug Administration (FDA) has granted Fast Tr...

2021-08-19 10:57 2347

MicroConstants to Join BioAgilytix Family

Highly complementary transaction strengthens BioAgilytix's ability to support bioanalytical services across all major therapeutics in development; adds LC/MS/MS capabilities; and expands team of seasoned scientists DURHAM, N.C., Aug. 18, 2021 /PRNewswire/ -- BioAgilytix Labs, LLC (BioAgilytix),...

2021-08-19 02:30 2169

Henlius reports half-year (H1) 2021 results, outlines remarkable growth in commercialization and needs-driven innovation

SHANGHAI, Aug. 18, 2021 /PRNewswire/ -- Henlius (2696.HK) announced Half-Year (H1) results endedJune 30th, 2021, sharing the company's recent noteworthy progress and achievements. As a global innovative biopharmaceutical company, Henlius is committed to offering high-quality, affordable and innov...

2021-08-18 21:35 4524

Holmusk signs agreements with UTHealth and The Harris Center

NEW YORK, Aug. 17, 2021 /PRNewswire/ -- Holmusk, a leading global data science and health technology company building the world's largest Real-World Evidence (RWE) platform for behavioral health, has signed data license agreements with TheUniversity of Texas Health Science Center at Houston (UTHe...

2021-08-17 21:00 2184

I-Mab to Provide Business and Corporate Updates and Report Financial Results for the Six Months Ended June 30, 2021 on August 31, 2021

SHANGHAI and GAITHERSBURG, Md., Aug. 17, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced it will provide business and corporate updates and repo...

2021-08-17 20:00 3432

PharmAbcine to Participate in Biotechgate Digital Partnering

DAEJEON, South Korea, Aug. 17, 2021 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next generation antibody therapeutics, announced today that the Company will participate in Biotechgate Digital Partnering taking place virtuall...

2021-08-17 20:00 1852

Angel Pharmaceuticals Announces IND Acceptance for Clinical Trial of ITK Inhibitor CPI-818 in China

JIAXING, China and BURLINGAME, Calif., Aug. 16, 2021 /PRNewswire/ -- Angel Pharmaceuticals Ltd. ("Angel Pharma") today announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has accepted its IND application for the initiation of a Phase 1/...

2021-08-17 05:00 2190

First Edition of World Conference on Early Detection of Cancer Set to Start in November in Hainan, China

GUANGZHOU and HAIKOU, China, Aug. 16, 2021 /PRNewswire/ -- Early detection and diagnosis of cancer is an essential enabler of curative treatment and an effective solution to boost the survival rates of cancer patients worldwide. In an effort to lead the way in innovative research and strategies f...

2021-08-16 22:13 2464

Myungsung C&M launches a new MARPE

BUCHEON, South Korea, Aug. 16, 2021 /PRNewswire/ -- Myungsung C&M, a Korean orthodontic product manufacturer, has recently released its new product, which is A+ Expander as MARPE that Myungsung C&M introduces. Myungsung CNM A+ Expander...

2021-08-16 21:00 2218

111, Inc. Deepens Partnership with Bayer Healthcare

SHANGHAI, Aug. 16, 2021 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services inChina, today announced the expansion of its existing partnership with Baye...

2021-08-16 20:00 7454

Gracell Biotechnologies Signs Exclusive License Agreement with FutureGen Biopharm to Develop Engineered Immune Cell Therapies Targeting Claudin 18.2 in Solid Tumors

SUZHOU and SHANGHAI, China, and PALO ALTO, Calif., Aug. 16, 2021 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today ...

2021-08-16 20:00 3288

Senhwa Completes Enrollment of a Phase 2 Investigator Initiated Trial of Silmitasertib as Novel Oral Drug for COVID-19

TAIPEI and SAN DIEGO, Aug. 16, 2021 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a new drug development company focused on human efficacy and innovation of first-in-class therapeutics for oncology, rare diseases, and novel coronaviruses, today announced that its novel oral drug, Silmita...

2021-08-16 15:29 2221

GeneQuantum announces a key leadership appointment

SUZHOU, China, Aug. 15, 2021 /PRNewswire/ -- GeneQuantum Healthcare, an industry leading biopharmacetucial company dedicated to next generation bioconjugate drugs through innovative intelligent ligase-dependent conjugation (iLDC) technology platform, announced a key appointment to further strengt...

2021-08-16 10:00 1803

InnoCare Announces First Subject Dosed in Clinical Trial of ICP-332

BEIJING, Aug. 15, 2021 /PRNewswire/ -- InnoCare (HKEX: 09969), a leading biopharmaceutical company focusing on drug innovation for cancer and autoimmune diseases, announced today the first subject dosed in clinical trial of novel TYK2 (Tyrosine Kinase 2) inhibitor ICP-332 inChina. InnoCare disc...

2021-08-16 09:32 8421

InxMed's IN10018 Receives U.S. FDA Fast Track Designation for the Treatment of Platinum-resistant Ovarian Cancer

NANJING, China, Aug. 15, 2021 /PRNewswire/ -- InxMed (Nanjing) Co., Ltd. ("InxMed" or "Company"), a clinical stage biotech company dedicated to developing innovative, individualized medicines with international impact, announced today the U.S. Food and Drug Administration (FDA) has granted Fas...

2021-08-16 09:31 2032

Arctic Vision Announces Expansion of License Territory for Suprachoroidal Space Injection Therapy ARVN001 to Include ASEAN Countries and India

SHANGHAI, Aug. 15, 2021 /PRNewswire/ -- Arctic Vision, a China-based biotech company focused on innovative ophthalmic therapies, announced today the entering of an amendment to the exclusive license agreement with its partner Clearside Biomedical, Inc. (Nasdaq: CLSD) ("Clearside"), to expand the ...

2021-08-16 08:00 8441

Senhwa Signs Agreement with Taiwan's CDE for COVID-19 Program Guiding Development of Silmitasertib

TAIPEI and SAN DIEGO, Aug. 13, 2021 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a drug development company focused on first-in-class therapeutics for oncology, rare diseases, and coronaviruses, today announced that its novel oral drug, Silmitasertib, has been included inTaiwan's Center...

2021-08-14 10:48 3627

Week's Top Stories